{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T13:48:58Z","timestamp":1776865738022,"version":"3.51.2"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,11,29]],"date-time":"2012-11-29T00:00:00Z","timestamp":1354147200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1007\/s10549-012-2348-2","type":"journal-article","created":{"date-parts":[[2012,11,29]],"date-time":"2012-11-29T12:55:37Z","timestamp":1354193737000},"page":"119-125","source":"Crossref","is-referenced-by-count":44,"title":["Evaluation of BRCA1 mutations in an unselected patient population with triple-negative breast cancer"],"prefix":"10.1007","volume":"137","author":[{"given":"Seth","family":"Rummel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Varner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig D.","family":"Shriver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel E.","family":"Ellsworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,11,29]]},"reference":[{"issue":"1","key":"2348_CR1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1080\/00313020802563510","volume":"41","author":"EA Rakha","year":"2009","unstructured":"Rakha EA, Ellis IO (2009) Triple-negative\/basal-like breast cancer: review. Pathology 41(1):40\u201347","journal-title":"Pathology"},{"issue":"3","key":"2348_CR2","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s10549-010-1293-1","volume":"125","author":"SK Pal","year":"2011","unstructured":"Pal SK, Childs BH, Pegram M (2011) Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat 125(3):627\u2013636","journal-title":"Breast Cancer Res Treat"},{"issue":"15 Pt 1","key":"2348_CR3","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15 Pt 1):4429\u20134434","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2348_CR4","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1002\/cncr.23930","volume":"113","author":"NU Lin","year":"2008","unstructured":"Lin NU, Claus E, Sohl J, Razzak AR, Amaout A, Winer EP (2008) Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 113(10):2638\u20132645","journal-title":"Cancer"},{"issue":"11","key":"2348_CR5","first-page":"1233","volume":"22","author":"C Anders","year":"2008","unstructured":"Anders C, Carey LA (2008) Understanding and treating triple-negative breast cancer. Oncology (Williston Park) 22(11):1233\u20131243","journal-title":"Oncology (Williston Park)"},{"issue":"26","key":"2348_CR6","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1200\/JCO.2008.16.6231","volume":"26","author":"DP Atchley","year":"2006","unstructured":"Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK (2006) Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 26(26):4282\u20134288","journal-title":"J Clin Oncol"},{"issue":"6","key":"2348_CR7","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/PAP.0b013e3181594733","volume":"14","author":"LK Diaz","year":"2007","unstructured":"Diaz LK, Cryns VL, Symmans F, Sneige N (2007) Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice. Adv Anat Pathol 14(6):419\u2013430","journal-title":"Adv Anat Pathol"},{"issue":"5","key":"2348_CR8","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1073\/pnas.0711613105","volume":"105","author":"S Liu","year":"2008","unstructured":"Liu S, Ginestier C, Charafe-Jauffret E, Foco H, Kleer CG, Merajver SD, Dontu G, Wicha MS (2008) BRCA1 regulates human mammary stem\/progenitor cell fate. Proc Natl Acad Sci USA 105(5):1680\u20131685","journal-title":"Proc Natl Acad Sci USA"},{"key":"2348_CR9","unstructured":"Silver DP (2011) PARP inhibition in triple negative breast cancer, November 8, 11"},{"key":"2348_CR10","volume-title":"AJCC cancer staging manual","author":"American Joint Committee on Cancer","year":"2010","unstructured":"American Joint Committee on Cancer (2010) AJCC cancer staging manual, 7th edn. Springer, New York","edition":"7"},{"key":"2348_CR11","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/bjc.1957.43","volume":"11","author":"HJ Bloom","year":"1957","unstructured":"Bloom HJ, Richardson WW (1957) Histological grading and prognosis in breast cancer. Br J Cancer 11:359\u2013377","journal-title":"Br J Cancer"},{"key":"2348_CR12","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1365-2559.1991.tb00229.x","volume":"19","author":"CW Elston","year":"1991","unstructured":"Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow up. Histopathology 19:403\u2013410","journal-title":"Histopathology"},{"issue":"16","key":"2348_CR13","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1200\/JCO.2009.25.6529","volume":"28","author":"MEH Hammond","year":"2010","unstructured":"Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL et al (2010) American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28(16):2784\u20132795","journal-title":"J Clin Oncol"},{"key":"2348_CR14","unstructured":"National Comprehensive Cancer Network (2012) Genetic\/familial high-risk assessment: breast and ovarian cancer. 1.2012"},{"key":"2348_CR15","doi-asserted-by":"crossref","first-page":"478","DOI":"10.2144\/19962003478","volume":"20","author":"KH Hecker","year":"1996","unstructured":"Hecker KH, Roux KH (1996) High and low annealing temperatures increase both specificity and yield in touchdown and step-down PCR. Biotechniques 20:478\u2013485","journal-title":"Biotechniques"},{"key":"2348_CR16","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10549-011-1711-z","volume":"130","author":"S Bayraktar","year":"2011","unstructured":"Bayraktar S, Gutierrez-Barrera AM, Liu D, Tasbas T, Akar U, Litton JK, Lin E, Albarracin CT, Meric-Bernstam F, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK (2011) Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat 130:145\u2013153","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"2348_CR17","doi-asserted-by":"crossref","first-page":"963","DOI":"10.4161\/cc.5.9.2713","volume":"5","author":"MD Tischkowitz","year":"2006","unstructured":"Tischkowitz MD, Foulkes WD (2006) The basal phenotype of BRCA1-related breast cancer: past, present and future. Cell Cycle 5(9):963\u2013967","journal-title":"Cell Cycle"},{"key":"2348_CR18","first-page":"1206","volume":"60","author":"R Lidereau","year":"2000","unstructured":"Lidereau R, Eisinger F, Champeme M-H, Nogues C, Bieche I, Birnbaum D, Pallud C, Jacquemier J, Sobol H (2000) Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer. Cancer Res 60:1206\u20131210","journal-title":"Cancer Res"},{"key":"2348_CR19","first-page":"1739","volume":"7","author":"J Chang","year":"2001","unstructured":"Chang J, Hilsenbeck SG, Sng JH, Wong J, Ragu GC (2001) Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients. Clin Cancer Res 7:1739\u20131742","journal-title":"Clin Cancer Res"},{"issue":"19","key":"2348_CR20","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1093\/jnci\/djg050","volume":"95","author":"WD Foulkes","year":"2003","unstructured":"Foulkes WD, Stafansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N, Trudel M, Akslen LA (2003) Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95(19):1482\u20131485","journal-title":"J Natl Cancer Inst"},{"issue":"14","key":"2348_CR21","doi-asserted-by":"crossref","first-page":"8418","DOI":"10.1073\/pnas.0932692100","volume":"100","author":"T Sorlie","year":"2003","unstructured":"Sorlie T, Tibshirania R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL, Botstein D (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100(14):8418\u20138423","journal-title":"Proc Natl Acad Sci USA"},{"key":"2348_CR22","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1471-2407-9-86","volume":"9","author":"SR Young","year":"2009","unstructured":"Young SR, Pilarski RT, Donenberg T, Shapiro C, Hammon LS, Miller J, Brooks KA, Cohen S, Tenenholz B, DeSai D, Zandvakili I, Royer R, Li S, Narod SR (2009) The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer 9:86","journal-title":"BMC Cancer"},{"key":"2348_CR23","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1136\/jmedgenet-2011-100006","volume":"48","author":"DG Evans","year":"2011","unstructured":"Evans DG, Howell A, Ward D, Lalloo F, Jones JL, Eccles DM (2011) Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer. J Med Genet 48:520\u2013522","journal-title":"J Med Genet"},{"issue":"5","key":"2348_CR24","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1158\/1078-0432.CCR-10-2560","volume":"17","author":"AM Gonzalez-Angulo","year":"2011","unstructured":"Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, Lanchbury JS, Stemke-Hale K, Hennessy BT, Arun BK, Hortobagyi GN, Do K-A, Mills GB, Meric-Bernstam F (2011) Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 17(5):1082\u20131089","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2348_CR25","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1002\/cncr.26576","volume":"118","author":"A-R Hartman","year":"2012","unstructured":"Hartman A-R, Kaldate RR, Sailer LM, Painter L, Crier CE, Endsley RR, Griffin M, Hamilton SA, Frye CA, Silberman MA, Wenstrup RJ, Sandbach JF (2012) Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer 118(11):2787\u20132795","journal-title":"Cancer"},{"issue":"16","key":"2348_CR26","doi-asserted-by":"crossref","first-page":"8297","DOI":"10.1158\/0008-5472.CAN-06-0503","volume":"66","author":"KE Malone","year":"2006","unstructured":"Malone KE, Daling JR, Doody DR, Hsu L, Bernstein L, Coates RJ, Marchbanks PA, Simon MS, McDonald JA, Norman SA, Strom BL, Burkman RT, Urslin G, Deapen D, Weiss LK, Folger S, Madeoy JJ, Friedrichsen DM, Suter NM, Humphrey MC, Spirtas R, Ostrander EA (2006) Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35\u201364\u00a0years. Cancer Res 66(16):8297\u20138308","journal-title":"Cancer Res"},{"key":"2348_CR27","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/humu.20169","volume":"25","author":"S Mazoyer","year":"2005","unstructured":"Mazoyer S (2005) Genomic rearrangements in the BRCA1 and BRCA2 genes. Hum Mutat 25:415\u2013422","journal-title":"Hum Mutat"},{"issue":"2","key":"2348_CR28","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1086\/302511","volume":"65","author":"HC Mefford","year":"1999","unstructured":"Mefford HC, Baumbach L, Panguluri RC, Whitfield-Broome C, Szabo C, Smith S, King MC, Dunston G, Stoppa-Lyonnet D, Arena F (1999) Evidence for a BRCA1 founder mutation in families of West African ancestry. Am J Hum Genet 65(2):575\u2013578","journal-title":"Am J Hum Genet"},{"issue":"5","key":"2348_CR29","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/ijc.27326","volume":"131","author":"JD Fackenthal","year":"2012","unstructured":"Fackenthal JD, Zhang J, Zhang B, Zheng Y, Hagos F, Burrill DR, Niu Q, Huo D, Sveen WE, Ogundiran T, Adebamowo C, Odetunde A, Falusi AG, Olopade OI (2012) High prevalence of BRCA1 and BRCA2 mutations in unselected Nigerian breast cancer patients. Int J Cancer 131(5):1114\u20131123","journal-title":"Int J Cancer"},{"issue":"21","key":"2348_CR30","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1001\/jama.295.21.2492","volume":"295","author":"LA Carey","year":"2006","unstructured":"Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edminston S, Deming SL, Geradts J, Cheang MCU, Nielson TO, Moorman PG, Earp HS, Milikan RC (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295(21):2492\u20132502","journal-title":"JAMA"},{"issue":"2","key":"2348_CR31","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s10549-012-2136-z","volume":"134","author":"J Zhang","year":"2012","unstructured":"Zhang J, Fackenthal JD, Zheng Y, Huo D, Hou N, Niu Q, Zvosec C, Ogundiran TO, Hennis AJ, Leske MC, Nemesure B, Wu S-Y, Olopade OI (2012) Recurrent BRCA1 and BRCA2 mutations in breast cancer patients of African ancestry. Breast Cancer Res Treat 134(2):889\u2013894","journal-title":"Breast Cancer Res Treat"},{"issue":"27","key":"2348_CR32","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1200\/JCO.2010.28.0719","volume":"28","author":"JS Kwon","year":"2010","unstructured":"Kwon JS, Gutierrez-Barrera AM, Young D, Sun CC, Daniels MS, Lu KH, Arun B (2010) Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol 28(27):4214\u20134220","journal-title":"J Clin Oncol"},{"key":"2348_CR33","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1200\/JCO.2008.16.0812","volume":"26","author":"A Ashworth","year":"2008","unstructured":"Ashworth A (2008) A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 26:3785\u20133790","journal-title":"J Clin Oncol"},{"issue":"2","key":"2348_CR34","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","volume":"361","author":"PC Fong","year":"2009","unstructured":"Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O\u2019Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361(2):123\u2013134","journal-title":"N Engl J Med"},{"issue":"3","key":"2348_CR35","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa1011418","volume":"364","author":"J O\u2019Shaughnessy","year":"2011","unstructured":"O\u2019Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, Koo IC, Sherman BM, Bradley C (2011) Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 364(3):205\u2013214","journal-title":"N Engl J Med"},{"issue":"9737","key":"2348_CR36","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","volume":"376","author":"A Tutt","year":"2010","unstructured":"Tutt A, Robson M, Garber JE, Domcheck SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376(9737):235\u2013244","journal-title":"Lancet"},{"issue":"9","key":"2348_CR37","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","volume":"12","author":"KA Gelmon","year":"2011","unstructured":"Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, Oza A (2011) Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 12(9):852\u2013861","journal-title":"Lancet Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-012-2348-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-012-2348-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-012-2348-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,6]],"date-time":"2019-07-06T06:24:53Z","timestamp":1562394293000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-012-2348-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,29]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["2348"],"URL":"https:\/\/doi.org\/10.1007\/s10549-012-2348-2","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,29]]}}}